标题：晚期甲状腺癌的临床治疗研究进展

      作者：李云超 1 综述 孙占峰 1，胡金朋 2，苏彬 2，王振国 2，王月明 1 审校    1.天津市宁河区医院普外科，天津 301500；2.武警特色医学中心研究部，天津 300162

      卷次： 2021年32卷21期

      【摘要】 甲状腺癌是最常见的恶性内分泌肿瘤，主要表现为颈部肿块，而甲状腺癌晚期患者其10年存活率较低。甲状腺癌一般采用多模式治疗，而对于无法手术切除的晚期患者，其治疗方法主要是放射性碘治疗或其他药物治疗。研究显示，在甲状腺癌的分子信号通路中，细胞膜上受体酪氨酸激酶、血管内皮生长因子(VEGF)等已成为治疗甲状腺癌的重要靶点，美国FDA已批准了多种新的靶向治疗方法用于晚期甲状腺癌，因此目前靶向治疗药物也是晚期甲状腺癌患者的标准治疗药物之一。本文将就晚期甲状腺癌的临床治疗研究进展进行综述。
      【关键词】 甲状腺癌；转染重排；靶向治疗；凡德他尼；卡博替尼；治疗进展
      【中图分类号】R736.1 【文献标识码】 A 【文章编号】 1003—6350（2021）21—2814—05

Advances in clinical treatment of advanced thyroid cancer.
LI Yun-chao 1, SUN Zhan-feng 1, HU Jin-peng 2, SU Bin 2,WANG Zhen-guo 2, WANG Yue-ming 1. 1. Department of General Surgery, Tianjin Ninghe District Hospital, Tianjin 301500,CHINA; 2. Department of Research, Armed Police Special Medical Center, Tianjin 300162, CHINA【Abstract】 Thyroid cancer is the most common malignant endocrine tumor, which is mainly manifested as aneck mass. In patients with advanced thyroid cancer, the 10-year survival rate is low. Thyroid cancer is generally treatedwith multiple modes, and for advanced patients who cannot be surgically removed, the treatment methods are mainly ra-dioactive iodine therapy or other drug therapy. Studies have shown that in the molecular signaling pathways of thyroidcancer, receptor tyrosine kinases and vascular endothelial growth factor (VEGF) have become important targets for thetreatment of thyroid cancer. The FDA has approved a variety of new targeted therapies for advanced thyroid cancer, sotargeted therapeutic drugs are currently one of the standard treatments for patients with advanced thyroid cancer. There-fore, this article will review the progress in the clinical treatment of advanced thyroid cancer.
      【Key words】 Thyroid cancer; Transfection rearrangement; Targeted therapy; Vandetanib; Cabozantinib; Treat-ment advances·综述·doi:10.3969/j.issn.1003-6350.2021.21.026基金项目：天津市科技计划项目(编号：16ZXHLSY00120、15ZXLCSY00040)；巨灾后武警部队医学救援力量模块化编组研究(编号：CWJ18L004)；武警后勤学院基础研究项目(编号：WHJ201721)